enasidenib inn trade name idhifa medication used treat relapsed refractory acute myeloid leukemia people specific mutations isocitrate dehydrogenase gene determined fdaapproved companion diagnostic inhibitor developed agios pharmaceuticals licensed celgene development us food drug administration fda considers firstinclass enasidenib used treat relapsed refractory acute myeloid leukemia people specific mutations gene determined fdaapproved companion diagnostic main serious adverse effect enasidenib differentiation isocitrate dehydrogenase critical enzyme citric acid cycle mutated forms idh produce high levels renantiomer contribute growth tumors catalyzes reaction cytoplasm catalyzes reaction mitochondria mutations common mutations compared affected aml enasidenib disrupts cycle decreasing total levels mitochondriamedical citation needed us food drug administration fda granted application enasidenib fast track designation orphan drug designation acute myeloid leukemia enasidenib approved fda august relapsed refractory acute myeloid leukemia aml people specific mutations gene determined fdaapproved companion diagnostic httpsenwikipediaorgwikienasidenib